LG Chem: LG Chem drops late-stage gout drug, shifts $270 mil. R&D focus to cancer after US blowback

Despite clearing phase 3 with flying colors, LG Chem just axed its most advanced gout drug-shutting down a global trial and shifting its R&D firepower to cancer, where the company sees a clearer commercial runway and faster payoff.The move ends EURELIA-2, a 2,600-patient trial comparing once-daily t